123 related articles for article (PubMed ID: 11185947)
1. Pindolol augmentation of antidepressants: a review and rationale.
Olver JS; Cryan JF; Burrows GD; Norman TR
Aust N Z J Psychiatry; 2000 Feb; 34(1):71-9. PubMed ID: 11185947
[TBL] [Abstract][Full Text] [Related]
2. Milnacipran and pindolol: a randomized trial of reduction of antidepressant latency.
Isaac MT; Isaac MB; Gallo F; Tournoux A
Hum Psychopharmacol; 2003 Dec; 18(8):595-601. PubMed ID: 14696018
[TBL] [Abstract][Full Text] [Related]
3. Pindolol augmentation of antidepressant therapy.
McAskill R; Mir S; Taylor D
Br J Psychiatry; 1998 Sep; 173():203-8. PubMed ID: 9926094
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of standard depression therapy.
Marangell LB
Clin Ther; 2000; 22 Suppl A():A25-38; discussion A39-41. PubMed ID: 10815648
[TBL] [Abstract][Full Text] [Related]
5. Treating antidepressant nonresponders with augmentation strategies: an overview.
Thase ME; Howland RH; Friedman ES
J Clin Psychiatry; 1998; 59 Suppl 5():5-12; discussion 13-5. PubMed ID: 9635543
[TBL] [Abstract][Full Text] [Related]
6. Fast onset: an open study of the treatment of major depressive disorder with nefazodone and pindolol combination therapy.
Bakish D; Hooper CL; Thornton MD; Wiens A; Miller CA; Thibaudeau CA
Int Clin Psychopharmacol; 1997 Mar; 12(2):91-7. PubMed ID: 9219044
[TBL] [Abstract][Full Text] [Related]
7. Augmentation strategies in patients with refractory depression.
Nemeroff CB
Depress Anxiety; 1996-1997; 4(4):169-81. PubMed ID: 9166649
[TBL] [Abstract][Full Text] [Related]
8. Treatment-resistant depression: no panacea, many uncertainties. Adverse effects are a major factor in treatment choice.
Prescrire Int; 2011 May; 20(116):128-33. PubMed ID: 21648180
[TBL] [Abstract][Full Text] [Related]
9. Potentiation strategies for treatment-resistant depression.
Ros S; Agüera L; de la Gándara J; Rojo JE; de Pedro JM
Acta Psychiatr Scand Suppl; 2005; (428):14-24, 36. PubMed ID: 16307616
[TBL] [Abstract][Full Text] [Related]
10. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency.
Tome MB; Isaac MT; Harte R; Holland C
Int Clin Psychopharmacol; 1997 Mar; 12(2):81-9. PubMed ID: 9219043
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological treatment of depression. Consulting with Dr Oscar.
Berber MJ
Can Fam Physician; 1999 Nov; 45():2663-8. PubMed ID: 10587774
[TBL] [Abstract][Full Text] [Related]
12. Augmentation strategies for treatment-resistant depression.
Carvalho AF; Machado JR; Cavalcante JL
Curr Opin Psychiatry; 2009 Jan; 22(1):7-12. PubMed ID: 19122528
[TBL] [Abstract][Full Text] [Related]
13. Augmentation strategies for treatment-resistant depression: a literature review.
Carvalho AF; Cavalcante JL; Castelo MS; Lima MC
J Clin Pharm Ther; 2007 Oct; 32(5):415-28. PubMed ID: 17875106
[TBL] [Abstract][Full Text] [Related]
14. Pindolol augmentation of serotonin reuptake inhibitors for the treatment of depressive disorder: a systematic review.
Whale R; Terao T; Cowen P; Freemantle N; Geddes J
J Psychopharmacol; 2010 Apr; 24(4):513-20. PubMed ID: 18832428
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors.
Pérez V; Puiigdemont D; Gilaberte I; Alvarez E; Artigas F;
J Clin Psychopharmacol; 2001 Feb; 21(1):36-45. PubMed ID: 11199945
[TBL] [Abstract][Full Text] [Related]
16. Treatment of antidepressant nonresponders: augmentation or switch?
Nelson JC
J Clin Psychiatry; 1998; 59 Suppl 15():35-41. PubMed ID: 9786309
[TBL] [Abstract][Full Text] [Related]
17. To combine or not to combine? A literature review of antidepressant combination therapy.
Dodd S; Horgan D; Malhi GS; Berk M
J Affect Disord; 2005 Dec; 89(1-3):1-11. PubMed ID: 16169088
[TBL] [Abstract][Full Text] [Related]
18. Rapid cycling triggered by pindolol augmentation of paroxetine, but not with desipramine.
Kraus RP
Depression; 1996; 4(2):92-4. PubMed ID: 9160648
[TBL] [Abstract][Full Text] [Related]
19. Pindolol augmentation of selective serotonin reuptake inhibitors: accounting for the variability of results of placebo-controlled double-blind studies in patients with major depression.
Segrave R; Nathan PJ
Hum Psychopharmacol; 2005 Apr; 20(3):163-74. PubMed ID: 15648095
[TBL] [Abstract][Full Text] [Related]
20. Pindolol augmentation of tranylcypromine in psychotic depression.
Kraus RP
J Clin Psychopharmacol; 1997 Jun; 17(3):225-6. PubMed ID: 9169970
[No Abstract] [Full Text] [Related]
[Next] [New Search]
